JP2010534469A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010534469A5 JP2010534469A5 JP2010517493A JP2010517493A JP2010534469A5 JP 2010534469 A5 JP2010534469 A5 JP 2010534469A5 JP 2010517493 A JP2010517493 A JP 2010517493A JP 2010517493 A JP2010517493 A JP 2010517493A JP 2010534469 A5 JP2010534469 A5 JP 2010534469A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- human
- kdr
- monoclonal
- vegf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95180507P | 2007-07-25 | 2007-07-25 | |
| PCT/GB2008/050615 WO2009013543A2 (en) | 2007-07-25 | 2008-07-23 | Targeted binging agents directed to kdr and uses thereof - 035 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010534469A JP2010534469A (ja) | 2010-11-11 |
| JP2010534469A5 true JP2010534469A5 (enExample) | 2011-09-08 |
Family
ID=40281893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010517493A Pending JP2010534469A (ja) | 2007-07-25 | 2008-07-23 | Ｋｄｒ指向性標的化結合物質およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8119130B2 (enExample) |
| EP (1) | EP2183028A2 (enExample) |
| JP (1) | JP2010534469A (enExample) |
| AU (1) | AU2008278803A1 (enExample) |
| CA (1) | CA2694396A1 (enExample) |
| WO (1) | WO2009013543A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009013543A2 (en) | 2007-07-25 | 2009-01-29 | Astrazeneca Ab | Targeted binging agents directed to kdr and uses thereof - 035 |
| JO3375B1 (ar) * | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| HUE029139T2 (hu) | 2011-02-10 | 2017-02-28 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| CN103087192B (zh) * | 2011-11-02 | 2015-02-04 | 埃派斯进有限公司 | 抗-kdr抗体和使用方法 |
| KR102027603B1 (ko) | 2011-11-02 | 2019-10-01 | 아펙시젠, 인코포레이티드 | 항-kdr 항체 및 사용 방법 |
| US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| JO3462B1 (ar) | 2012-08-22 | 2020-07-05 | Regeneron Pharma | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها |
| CA2881966C (en) | 2012-08-24 | 2020-10-06 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
| EP2895512B1 (en) * | 2012-09-12 | 2018-07-04 | Neurimmune Holding AG | Human islet amyloid polypeptide (hiapp) specific antibodies and uses thereof |
| RS58149B1 (sr) | 2014-02-06 | 2019-02-28 | Hoffmann La Roche | Fuzioni proteini interleukina-2 i njihova upotreba |
| KR20180021136A (ko) * | 2015-06-30 | 2018-02-28 | 헨리우스 바이오테크 컴퍼니 리미티드 | 항-혈관 내피 성장 인자 수용체 2 (vegfr2) 항체 |
| EP3474854A4 (en) | 2016-06-27 | 2020-02-19 | The Regents of The University of California | CANCER TREATMENT COMBINATIONS |
| US20200095327A1 (en) * | 2017-02-08 | 2020-03-26 | Dragonfly Therapeutics, Inc. | Antibody heavy chain variable domains targeting the nkg2d receptor |
| DK3579848T3 (da) | 2017-02-08 | 2025-01-20 | Dragonfly Therapeutics Inc | Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft |
| KR20240060739A (ko) | 2017-02-20 | 2024-05-08 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
| EP3595720A4 (en) | 2017-03-14 | 2021-05-26 | Five Prime Therapeutics, Inc. | ANTIBODIES BINDING VISTA AT ACIDIC PH VALUE |
| WO2019084053A1 (en) * | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
| EP3700568A4 (en) | 2017-10-24 | 2021-11-10 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
| US10882915B2 (en) | 2017-10-24 | 2021-01-05 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD117+ cells |
| SG11202007482WA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
| SG11202007579TA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| JP7353576B2 (ja) | 2018-02-20 | 2023-10-02 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法 |
| MX2020009786A (es) | 2018-03-21 | 2020-10-12 | Five Prime Therapeutics Inc | Anticuerpos de union a supresor de la activacion de celulas t que contiene el dominio variable de inmunoglobulina (vista) a ph acido. |
| WO2020014327A2 (en) | 2018-07-11 | 2020-01-16 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic ph |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| EP3833385A4 (en) | 2018-08-08 | 2021-12-22 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN |
| CN115836088A (zh) | 2020-05-06 | 2023-03-21 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和clec12a的蛋白质 |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| JP2024528038A (ja) | 2021-07-29 | 2024-07-26 | ソノマ バイオセラピューティクス， インコーポレイテッド | 調節性ｔ細胞を標的として自己免疫疾患を処置するための滑膜細胞外マトリックス特異的キメラ抗原受容体 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2450793A1 (en) | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| US20040242851A1 (en) * | 2001-06-26 | 2004-12-02 | Zhenping Zhu | Bispecific antibodies that bind to vegf receptors |
| US7498414B2 (en) * | 2002-03-04 | 2009-03-03 | Imclone Systems Incorporated | Human antibodies specific to KDR and uses thereof |
| WO2009013543A2 (en) | 2007-07-25 | 2009-01-29 | Astrazeneca Ab | Targeted binging agents directed to kdr and uses thereof - 035 |
-
2008
- 2008-07-23 WO PCT/GB2008/050615 patent/WO2009013543A2/en not_active Ceased
- 2008-07-23 JP JP2010517493A patent/JP2010534469A/ja active Pending
- 2008-07-23 CA CA2694396A patent/CA2694396A1/en not_active Abandoned
- 2008-07-23 AU AU2008278803A patent/AU2008278803A1/en not_active Abandoned
- 2008-07-23 EP EP08788590A patent/EP2183028A2/en not_active Withdrawn
- 2008-07-23 US US12/669,724 patent/US8119130B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014503189A5 (enExample) | ||
| JP2014530215A5 (enExample) | ||
| JP2013527761A5 (enExample) | ||
| JP2019519199A5 (enExample) | ||
| JP2015227342A5 (enExample) | ||
| JP2018108081A5 (enExample) | ||
| JP2012012402A5 (enExample) | ||
| JP2017523786A5 (enExample) | ||
| HRP20161069T1 (hr) | Molekule antitijela koje vezuju il-17a i il-17f | |
| JP2015517300A5 (enExample) | ||
| JP2010506596A5 (enExample) | ||
| JP2010507594A5 (enExample) | ||
| JP2009531283A5 (enExample) | ||
| JP2021524275A5 (enExample) | ||
| JP2020504076A5 (enExample) | ||
| JP2011515073A5 (enExample) | ||
| JP2017507657A5 (enExample) | ||
| JP2017504577A5 (enExample) | ||
| CA2798390A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| JP2010535032A5 (enExample) | ||
| JP2015212281A5 (enExample) | ||
| JP2013523166A5 (enExample) | ||
| CL2010001544A1 (es) | Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma. | |
| FI3736291T3 (fi) | Anti-fcrh5-vasta-aineita | |
| ME02607B (me) | Molekuli antitela koji imaju specifično vezivanje za humani il-13 |